Download PDF
Der Klinikarzt 2017; 46(12): 624-629
DOI: 10.1055/s-0043-122590
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Sarkopenie

Ein geriatrisches Syndrom zwischen Forschung und Klinik
Dominik Spira
1   Charité – Universitätsmedizin Berlin, Interdisziplinäres Stoffwechselzentrum, Arbeitsbereich Lipidstoffwechsel und Altersmedizin
,
Elisabeth Steinhagen-Thiessen
1   Charité – Universitätsmedizin Berlin, Interdisziplinäres Stoffwechselzentrum, Arbeitsbereich Lipidstoffwechsel und Altersmedizin
2   Universitätsmedizin Greifswald und Kreiskrankenhaus Wolgast, Altersmedizinisches Zentrum
,
Kristina Norman
3   Charité – Universitätsmedizin Berlin, Forschungsgruppe Geriatrie an der Charité
,
Rahel Eckardt-Felmberg
4   St. Joseph Krankenhaus Berlin, Klinik für Geriatrie
› Author Affiliations
Further Information

Publication History

Publication Date:
20 December 2017 (online)

Also available at
    Permissions and Reprints

Unter Sarkopenie versteht man den altersassoziierten Verlust an Muskelmasse und -funktion, der mit zunehmendem Ausmaß erhebliche klinische Relevanz besitzt, z. B. was die selbstständige Ausführung der Aktivitäten des täglichen Lebens angeht. Mittlerweile existieren ein ICD-10-CM-Code und mehrere von Fachgesellschaften und in Konsensusdokumenten festgeschriebene diagnostische Kriterien. Die vorliegende Arbeit gibt einen Überblick über die Prävalenz, die zugrunde liegende Pathophysiologie sowie die Folgen der Sarkopenie. Ein weiterer Schwerpunkt sind die Methoden und Problemstellungen in der Diagnostik und die nach aktuellem Kenntnisstand möglichen therapeutischen Ansätze.

 

  • Literatur

  • 1 Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr 1997; 127 (Suppl. 05) 990s-991s
    CrossrefPubMedGoogle Scholar
  • 2 Janssen I, Shepard DS, Katzmarzyk PT. et al. The Healthcare Costs of Sarcopenia in the United States. J Am Geriatr Soc 2004; 52: 80-85
    CrossrefPubMedGoogle Scholar
  • 3 Anker SD, Morley JE, von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle 2016; 7: 512-514
    CrossrefPubMedGoogle Scholar
  • 4 Dennison EM, Sayer AA, Cooper C. Epidemiology of sarcopenia and insight into possible therapeutic targets. Nat Rev Rheumatol 2017; 13: 340-347
    CrossrefPubMedGoogle Scholar
  • 5 Shafiee G, Keshtkar A, Soltani A. et al. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diabetes Metab Disord 2017; 16: 21
    CrossrefPubMedGoogle Scholar
  • 6 Ferrucci L, Russo CR, Lauretani F. et al. A role for sarcopenia in late-life osteoporosis. Aging Clin Exp Res 2002; 14: 1-4
    CrossrefPubMedGoogle Scholar
  • 7 von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle 2010; 1: 129-133
    CrossrefPubMedGoogle Scholar
  • 8 Morley JE. Frailty and sarcopenia: the new geriatric giants. Rev Invest Clin 2016; 68: 59-67
    PubMedGoogle Scholar
  • 9 Roth SM. Genetic aspects of skeletal muscle strength and mass with relevance to sarcopenia. Bonekey Rep 2012; 1: 58
    PubMedGoogle Scholar
  • 10 Vitale G, Cesari M, Mari D. Aging of the endocrine system and its potential impact on sarcopenia. Eur J Int Med 2016; 35: 10-15
    CrossrefPubMedGoogle Scholar
  • 11 Ochi M, Kohara K, Tabara Y. et al. Arterial stiffness is associated with low thigh muscle mass in middle-aged to elderly men. Atherosclerosis 2010; 212: 327-332
    CrossrefPubMedGoogle Scholar
  • 12 Calvani R, Joseph AM, Adhihetty PJ. et al. Mitochondrial pathways in sarcopenia of aging and disuse muscle atrophy. Biol Chem 2013; 394: 393-414
    PubMedGoogle Scholar
  • 13 Bano G, Trevisan C, Carraro S. et al. Inflammation and sarcopenia: A systematic review and meta-analysis. Maturitas 2017; 96: 10-15
    CrossrefPubMedGoogle Scholar
  • 14 Campins L, Camps M, Riera A. et al. Oral drugs related with muscle wasting and sarcopenia. A review. Pharmacology 2017; 99: 1-8
    CrossrefPubMedGoogle Scholar
  • 15 Visser M, Goodpaster BH, Kritchevsky SB. et al. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci 2005; 60: 324-333
    CrossrefPubMedGoogle Scholar
  • 16 Cesari M, Pahor M, Lauretani F. et al. Skeletal muscle and mortality results from the InCHIANTI Study. J Gerontol A Biol Sci Med Sci 2009; 64: 377-384
    CrossrefPubMedGoogle Scholar
  • 17 Cooper R, Kuh D, Hardy R. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ 2010; 341: c4467
    CrossrefPubMedGoogle Scholar
  • 18 Tosato M, Marzetti E, Cesari M. et al. Measurement of muscle mass in sarcopenia: from imaging to biochemical markers. Aging Clin Exp Res 2017; 29: 19-27
    CrossrefPubMedGoogle Scholar
  • 19 Cruz-Jentoft AJ, Baeyens JP, Bauer JM. et al. : Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-423
    CrossrefPubMedGoogle Scholar
  • 20 Cawthon PM, Peters KW, Shardell MD. et al. Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci 2014; 69: 567-575
    CrossrefPubMedGoogle Scholar
  • 21 Spira D, Buchmann N, Nikolov J. et al. Association of low lean mass with frailty and physical performance: a comparison between two operational definitions of sarcopenia. data from the Berlin Aging Study II (BASE-II). J Gerontol A Biol Sci Med Sci 2015; 70: 779-784
    CrossrefPubMedGoogle Scholar
  • 22 Studenski SA, Peters KW, Alley DE. et al. The FNIH Sarcopenia Project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci 2014; 69: 547-558
    CrossrefPubMedGoogle Scholar
  • 23 Malmstrom TK, Miller DK, Simonsick EM. et al. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle 2016; 7: 28-36
    CrossrefPubMedGoogle Scholar
  • 24 Yoshimura Y, Wakabayashi H, Yamada M. Interventions for treating sarcopenia: a systematic review and meta-Analysis of randomized controlled studies. J Am Med Dir Assoc 2017; 18 553.e1–553.e16
    PubMedGoogle Scholar
  • 25 Beaudart C, Dawson A, Shaw SC. et al. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporos Int 2017; 28: 1817-1833
    CrossrefPubMedGoogle Scholar
  • 26 Bouillon R. Can vitamin D prevent falls and fractures?. Lancet Diabetes Endocrinol 2017; 5: 407-409
    CrossrefPubMedGoogle Scholar
  • 27 Witham MD, Syddall HE, Dennison E. et al. ACE inhibitors, statins and thiazides: no association with change in grip strength among community dwelling older men and women from the Hertfordshire Cohort Study. Age Ageing 2014; 43: 661-666
    CrossrefPubMedGoogle Scholar
  • 28 Steffl M, Bohannon RW, Sontakova L. et al. Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging 2017; 12: 835-845
    CrossrefPubMedGoogle Scholar
  • 29 Eibich P, Buchmann N, Kroh M. et al. Exercise at different ages and appendicular lean mass and strength in later life: results from the Berlin Aging Study II. J Gerontol A Biol Sci Med Sci 2016; 71: 515-520
    CrossrefPubMedGoogle Scholar